4'-四氢吡喃基甘氨酸 | 53284-84-7

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4'-四氢吡喃基甘氨酸
• 中文别名: 氨基(四氢-2H-吡喃-4-基)乙酸；4’-四氢吡喃基甘氨酸
• 英文名称: amino(oxan-4-yl)acetic acid
• 英文别名: 2-azaniumyl-2-(oxan-4-yl)acetate
• CAS: 53284-84-7
• 化学式: C₇H₁₃NO₃
• mdl: MFCD02183576
• 分子量: 159.185
• InChiKey: XLZJPHKIECMDPG-UHFFFAOYSA-N

物化性质

• 沸点：
  316.7±17.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4’-Tetrahydropyranylglycine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4’-Tetrahydropyranylglycine
CAS number: 53284-84-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H13NO3
Molecular weight: 159.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4'-四氢吡喃基甘氨酸 在 4-二甲氨基吡啶 、 tris-(dibenzylideneacetone)dipalladium(0) 、 lithium aluminium tetrahydride 、 四丁基氟化铵 、 caesium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 乙二胺 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 115.0h， 生成 4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-N-[(3S)-5-nitro-3-(oxan-4-yl)-3,4-dihydro-2H-1,4-benzoxazin-7-ylsulfonyl]-2-[14-oxa-2,4,10-triazatricyclo[7.5.0.0[3,7]]tetradeca-1(9),2,5,7-tetraen-10-yl]benzamide
  参考文献：
  名称：

  [EN] CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS
  [FR] HÉTÉROCYCLES CONDENSÉS EN TANT QU'INHIBITEURS DE BCL-2

  摘要：

  公开号：

  WO2021066873A8
• 作为产物：
  描述：

  4-醛基四氢吡喃 、 氰化钾 在 甲醇 、 ammonium chloride 作用下， 生成 4'-四氢吡喃基甘氨酸
  参考文献：
  名称：

  Prelog; Cerkovnikov, Collection of Czechoslovak Chemical Communications, 1937, vol. 9, p. 22,26

  摘要：

  DOI：

文献信息

• PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
  申请人：Long Daniel D.

  公开号：US20130287730A1

  公开（公告）日：2013-10-31

  The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

  这项发明提供了式(I)的化合物： 其中变量在规范中定义，或其药用盐，这些化合物是乙型肝炎病毒复制的抑制剂。该发明还提供了包括这些化合物的药物组合物，使用这些化合物治疗乙型肝炎病毒感染的方法，以及用于制备这些化合物的工艺和中间体。
• [EN] OXAZEPINE DERIVATIVES HAVING TNAP INHIBITORY ACTIVITY<br/>[FR] DÉRIVÉS D'OXAZÉPINE AYANT UNE ACTIVITÉ INHIBITRICE DE TNAP
  申请人：DAIICHI SANKYO CO LTD

  公开号：WO2018119449A1

  公开（公告）日：2018-06-28

  The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有优异的组织非特异性碱性磷酸酶抑制活性的化合物或其药理学上可接受的盐。本发明提供一种由式(I)表示的化合物或其药理学上可接受的盐。
• HEPATITIS C VIRUS INHIBITORS
  申请人：McKinnell Robert Murray

  公开号：US20130287731A1

  公开（公告）日：2013-10-31

  The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

  这项发明提供了以下式(I)或(II)的化合物： 其中变量在规范中定义，或其药用盐，这些化合物是乙型肝炎病毒复制的抑制剂。该发明还提供了包括这些化合物的药物组合物，使用这些化合物治疗乙型肝炎病毒感染的方法，以及用于制备这些化合物的工艺和中间体。
• Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform
  作者：Shishir M. Pant、Amanda Mukonoweshuro、Bimbisar Desai、Manoj K. Ramjee、Christopher N. Selway、Gary J. Tarver、Adrian G. Wright、Kristian Birchall、Timothy M. Chapman、Topi A. Tervonen、Juha Klefström

  DOI：10.1021/acs.jmedchem.7b01698

  日期：2018.5.24

  role in hepatocyte growth factor (HGF) signaling and epithelial integrity makes it a target of therapeutic interest in carcinogenesis and metastasis. Using an integrated design, synthesis, and screening platform, we were able to rapidly develop potent and selective inhibitors of hepsin. In progressing from the initial hit 7 to compound 53, the IC50 value against hepsin was improved from ∼1 μM to 22

  肝素是一种膜锚定的丝氨酸蛋白酶，其在肝细胞生长因子（HGF）信号传导和上皮完整性中的作用使其成为癌变和转移的治疗靶标。使用集成的设计，合成和筛选平台，我们能够快速开发出有效的和选择性的肝素抑制剂。从最初的命中7到化合物53的过程中，针对肝素的IC 50值从约1μM提高到22 nM，并且对尿激酶型纤溶酶原激活剂（uPA）的选择性从30倍增加至> 6000倍。随后的体外ADMET分析和细胞研究证实，领先的化合物是用于研究肝素在乳腺肿瘤发生中的作用的有用工具。
• [EN] HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR<br/>[FR] DISPERSIONS SOLIDES EXTRUDÉES À CHAUD CONTENANT UN INHIBITEUR DE BCL2
  申请人：NEWAVE PHARMACEUTICAL INC

  公开号：WO2021173523A1

  公开（公告）日：2021-09-02

  A pro-apoptotic solid dispersion comprises, a Bcl -2 family protein inhibitory compound of Formula A as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier, and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula A, the water-soluble polymeric carrier, and the surfactant to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier, and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl -2 family proteins, for example cancer or an immune or autoimmune disease.

  一种促凋亡的固体分散物包括本文所定义的Formula A的Bcl-2家族蛋白抑制化合物，分散在包括（a）药学上可接受的水溶性聚合物载体和（b）药学上可接受的表面活性剂的固体基质中。制备这种固体分散物的方法包括将Formula A的化合物、水溶性聚合物载体和表面活性剂置于高温下，以提供可挤出的半固体混合物；挤出半固体混合物；并冷却所得挤出物，以提供包含聚合物载体和表面活性剂的固体基质，并且其中的化合物以基本非晶形式分散其中。这种固体分散物适用于口服给予需要治疗由一个或多个抗凋亡Bcl-2家族蛋白过度表达所特征的疾病的患者，例如癌症或免疫或自身免疫疾病。